Advance Search
YANG Ti, ZHANG Dailing, WAN Qijun, ZHANG Ying, GAO Yulu. Effect and action mechanism of luteolin on cell growth of colon cancer[J]. Journal of Clinical Medicine in Practice, 2022, 26(12): 84-90. DOI: 10.7619/jcmp.20214145
Citation: YANG Ti, ZHANG Dailing, WAN Qijun, ZHANG Ying, GAO Yulu. Effect and action mechanism of luteolin on cell growth of colon cancer[J]. Journal of Clinical Medicine in Practice, 2022, 26(12): 84-90. DOI: 10.7619/jcmp.20214145
shu

Effect and action mechanism of luteolin on cell growth of colon cancer

  • Clinical Laboratory Department, Kunshan Hospital of Traditional Chinese Medicine, Kunshan, Jiangsu, 215300

More Information
  • Received Date: October 21, 2021
  • Available Online: June 21, 2022
    Graphical Abstract
    • Abstract
  • Objective 

    To investigate the effect of luteolin on the growth of colon cancer cells, and to further clarify whether luteolin inhibits tumor growth or not by regulating the activity of immune cells.

    Methods 

    Mouse colon cancer cell lines (MC-38, CT-26, CMT-93) and human colon cancer cell lines (Caco-2) were cultured in vitro, the effects of luteolin on proliferation, apoptosis and migration of colon cancer cells at different concentrations (0, 1, 5, 10, 20 μmol/L)were observed. The tumor bearing model of mouse colon cancer cell MC-38 was constructed to observe the effects of luteolin on tumor growth, apoptosis and migration of cancer cells. The effect of luteolin on activity of mouse spleen immune cells and human peripheral blood lymphocytes was detected in vitro.

    Results 

    Luteolin at concentration of 5 μmol/L significantly inhibited the proliferation of mouse colon cancer cell line CT-26; luteolin at concentration of 10 μmol/L significantly inhibited the proliferation of mouse colon cancer cell line MC-38 and CMT-93; luteolin at concentration of 20 μmol/L significantly inhibited the proliferation of human colon cancer cell line Caco-2. Luteolin significantly inhibited the division and apoptosis of mouse colon cancer cell line CT-26, and significantly inhibited the migration of mouse colon cancer cell line MC-38. Treatment with luteolin at 20 mg/kg body weight significantly inhibited tumor growth and prolonged survival of colon cancer MC-38 bearing mice in vivo. In vitro different concentrations of luteolin stimulation did not affect the proliferation of mouse spleen immune cells, but significantly upregulated the expression of NKG2D on mouse CD8+T cells and natural killer (NK) cells. Luteolin at concentration of 10 μmol/L (effect target ratio of 3 to 1) could significantly up-regulate the killing activity of CD8+ T cells and NK cells against target cells. Luteolin stimulation up-regulated expressions of CD69 and NKG2D in human peripheral blood CD8+T cells in vitro.

    Conclusion 

    Luteolin inhibits the growth of colorectal cancer cells, promotes the activity of immune cells and inhibits tumor growth.

    • FullText(HTML)
    • References (10)
  • [1]
    SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA a Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
    [2]
    中华人民共和国国家卫生健康委员会. 中国结直肠癌诊疗规范(2020年版)[J]. 中华外科杂志, 2020, 58(8): 561-585. doi: 10.3760/cma.j.cn112139-20200518-00390
    [3]
    莫景颖, 罗笑珊, 张海怡, 等. 木犀草素抗肿瘤作用研究概况[J]. 亚太传统医药, 2021, 17(2): 177-181. https://www.cnki.com.cn/Article/CJFDTOTAL-YTCT202102057.htm
    [4]
    姚薛超, 宁洪鑫, 黄欢, 等. 木犀草素制剂的研究进展[J]. 中草药, 2021, 52(3): 873-882. https://www.cnki.com.cn/Article/CJFDTOTAL-ZCYO202103032.htm
    [5]
    LIN Y, SHI R X, WANG X, et al. Luteolin, a flavonoid with potential for cancer prevention and therapy[J]. Curr Cancer Drug Targets, 2008, 8(7): 634-646. doi: 10.2174/156800908786241050
    [6]
    KANG K A, PIAO M J, RYU Y S, et al. Luteolin induces apoptotic cell death via antioxidant activity in human colon cancer cells[J]. Int J Oncol, 2017, 51(4): 1169-1178. doi: 10.3892/ijo.2017.4091
    [7]
    FU C M, JIANG A M. Dendritic cells and CD8 T cell immunity in tumor microenvironment[J]. Front Immunol, 2018, 9: 3059. doi: 10.3389/fimmu.2018.03059
    [8]
    ST PAUL M, OHASHI P S. The roles of CD8+ T cell subsets in antitumor immunity[J]. Trends Cell Biol, 2020, 30(9): 695-704. doi: 10.1016/j.tcb.2020.06.003
    [9]
    ZHANG J Y, BASHER F, WU J D. NKG2D ligands in tumor immunity: two sides of a coin[J]. Front Immunol, 2015, 6: 97.
    [10]
    彭清, 孙柳, 苗雪圆, 等. 天然产物化合物作为肿瘤免疫调节剂的研究进展[J]. 中国中西医结合外科杂志, 2021, 27(1): 136-140. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZX202101034.htm
    • Related Articles

  • Cited by

    Periodical cited type(2)

    1. 刘媛，张红瑾，刘佳. 血清成纤维细胞生长因子23、S100A12对老年糖尿病患者动脉粥样硬化性心血管病的预测价值. 实用临床医药杂志. 2024(06): 99-103 . 本站查看
    2. 于单，袁行侠，汪浩. 2型糖尿病并发冠心病的影响因素分析. 系统医学. 2022(23): 100-103 .

    Other cited types(0)

Catalog

    Get Citation
    PDF
    XML
    Article views (225) PDF downloads (12) Cited by(2)
    Turn off MathJax
    Article Contents
    Abstract
    References

    © 2020 《实用临床医药杂志》编辑部

    Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    Supported by: Beijing Renhe Information Technology Co., Ltd.   Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return